Lamivudine Dolutegravir Tablets Detailed Instructions

1. Indications and Usage

Lamivudine dolutegravir tablets(Dolutegravir)isdolutegravir (integrase strand transfer inhibitor) and lamivudine (nucleoside similar A two-drug combination containing a reverse transcriptase inhibitor (RTI) as a complete regimen for the treatment of HIV-1 infection in adults without a history of antiretroviral therapy, or as an alternative to current virological suppression (HIV-1 An antiretroviral treatment regimen with RNAless than50copies/mL) with no history of treatment failure and no known surrogates associated with resistance to individual components of lamivudine dolutegravir tablets.

2. Dosage and usage

•Test patients for hepatitis B virus (HBV) infection before or while startinglamivudine dolutegravir tablets.

•Pregnancy Test:It is recommended that individuals of childbearing potential take a pregnancy test before starting Lamivudine Dolutegravir Tablets.

•Take one tablet daily, with or without food.

•The dosage of dolutegravir in lamivudine dolutegravir tablets (50 mg ) is insufficient when used concomitantly with carbamazepine or rifampicin. If lamivudine dolutegravir is taken with carbamazepine or rifampicin, take one dolutegravir tablet daily and then one dolutegravir 50-mg tablet about 12 hours after lamivudine dolutegravir . (2.3)

Three. Dosage form and strength

Tablets: 50 mg dolutegravir and 300mg lamivudine.

Four. Contraindications

•Previous allergic reaction to dolutegravir or lamivudine.

•Combined with dofetilide.

Five. Warnings and Precautions

•Hypersensitivity reactions, manifesting as rash, constitutional findings, and sometimes organ dysfunction, including liver damage, have been reported with dolutegravir. If signs or symptoms of an allergic reaction occur, discontinue lamivudine dolutegravir immediately as delayed discontinuation of treatment may result in a life-threatening reaction.

•Hepatotoxicity has been reported in patients receiving dolutegravircontaining regimens. Use of lamivudine dolutegravir in patients with underlying hepatitis B or C may increase the risk of worsening or development of elevated transaminases. Monitoring for hepatotoxicity is recommended.

•Embryo-Fetal toxicity may occur when used during conception and early pregnancy. Assess the risks and benefits of lamivudine dolutegravir and discuss with the patient to determine whether alternative treatments should be considered from the time of conception to the first trimester or if pregnancy should be confirmed in the first trimester due to the risk of neural tube defects. Persons of childbearing potential should be advised to consistently use effective contraceptive methods.

•Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have occurred with the use of nucleoside analogues.

•Immune reconstitution syndrome has been reported in patients receiving combination antiretroviral therapy.

6. Adverse reactions

The most common adverse reactions (all grades) observed in ≥2% of patients receiving lamivudine dolutegravir tablets were headache, nausea, diarrhea, insomnia, fatigue, and anxiety.

7. Drug interactions

•Lamivudine Dolutegravir Tablets is a complete regimen for the treatment of HIV-1 infection; therefore, it is not recommended to be used in combination with other antiretroviral drugs for the treatment of HIV-1 infection.

8. Use among specific groups of people

•Pregnancy:Evaluate the risks and benefits of lamivudine dolutegravir tablets and discuss them with the patient to determine whether alternative treatments should be considered from the time of conception to the first trimester or whether pregnancy should be confirmed in the first trimester due to the risk of neural tube defects.

•Breastfeeding:Breastfeeding is not recommended due to potential HIV-1 virus transmission.

•Women and men of childbearing potential:It is recommended that people of childbearing potential take a pregnancy test. Patients should be advised to consistently use effective contraceptive methods.

•Renal impairment:Dovastatin is not recommended for patients with creatinine clearance less than30 mL/min.

•Hepatic Impairment:Patients with severe hepatic impairment (Child-Pugh score of C) are not recommended to useLamivudine Dolutegravir Tablets.

The retail price in Indian pharmacies is around 300 yuan per box. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.

xa0

xa0